About: Sublingual apomorphine as a neuroendocrine probe     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:seeAlso
Description
  • Subcutaneous apomorphine, a dopaminergic agonist, is used as a neuroendocrine probe for assessing central dopaminergic activity. The aim of our study was to test sublingual apomorphine for the same purpose. We administered sublingual apomorphine in a weight-dependent dose (0.033 mg/kg) to 42 healthy men. Prolactin and growth hormone levels were measured before and after the administration at 15, 30, 45, 60, 75, 90, 120, 150 and 180 min. Subjects filled in Zung's self-assessment scores of anxiety (SAS) and depression (SDS) questionnaires before and after the test. Areas under the curve for prolactin and growth hormone levels were calculated using the trapezoidal rule. All subjects showed decreased prolactin, and 40/42 subjects showed increased growth hormone, in response to sublingual apomorphine. Average peak value for prolactin was - 4.6 ± 1.8 μg/l. Average peak value for growth hormone was 8.1 ± 8.5 ng/ml for the whole group, and 9.6 ± 8.1 ng/ml after exclusion of two negative growth hormone responders. Sublingual apomorphine produced no major side effects. Significant decreases in SAS (21.5 ± 5.7 vs. 20.6 ± 5.5) and SDS (9.7 ± 7.8 vs. 7.8 ± 6.8) scores were observed after the test. Sublingually administered apomorphine appears to be well tolerated and useful as a neuroendocrine marker of central dopaminergic activity.
  • Subcutaneous apomorphine, a dopaminergic agonist, is used as a neuroendocrine probe for assessing central dopaminergic activity. The aim of our study was to test sublingual apomorphine for the same purpose. We administered sublingual apomorphine in a weight-dependent dose (0.033 mg/kg) to 42 healthy men. Prolactin and growth hormone levels were measured before and after the administration at 15, 30, 45, 60, 75, 90, 120, 150 and 180 min. Subjects filled in Zung's self-assessment scores of anxiety (SAS) and depression (SDS) questionnaires before and after the test. Areas under the curve for prolactin and growth hormone levels were calculated using the trapezoidal rule. All subjects showed decreased prolactin, and 40/42 subjects showed increased growth hormone, in response to sublingual apomorphine. Average peak value for prolactin was - 4.6 ± 1.8 μg/l. Average peak value for growth hormone was 8.1 ± 8.5 ng/ml for the whole group, and 9.6 ± 8.1 ng/ml after exclusion of two negative growth hormone responders. Sublingual apomorphine produced no major side effects. Significant decreases in SAS (21.5 ± 5.7 vs. 20.6 ± 5.5) and SDS (9.7 ± 7.8 vs. 7.8 ± 6.8) scores were observed after the test. Sublingually administered apomorphine appears to be well tolerated and useful as a neuroendocrine marker of central dopaminergic activity. (en)
Title
  • Sublingual apomorphine as a neuroendocrine probe
  • Sublingual apomorphine as a neuroendocrine probe (en)
skos:prefLabel
  • Sublingual apomorphine as a neuroendocrine probe
  • Sublingual apomorphine as a neuroendocrine probe (en)
skos:notation
  • RIV/00023752:_____/12:43913801!RIV13-MZ0-00023752
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • I, V, Z(MSM0021620814)
http://linked.open...iv/cisloPeriodika
  • 2
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 172334
http://linked.open...ai/riv/idVysledku
  • RIV/00023752:_____/12:43913801
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • growth hormone; prolactin; neuroendocrine probe; sublingual apomorphine (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • IE - Irsko
http://linked.open...ontrolniKodProRIV
  • [6180256002B7]
http://linked.open...i/riv/nazevZdroje
  • Psychiatry Research
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 198
http://linked.open...iv/tvurceVysledku
  • Horáček, Jiří
  • Potočková, Jana
  • Řehula, Milan
  • Anděl, Michal
  • Brunerová, Ludmila
  • Kopřivová, Helena
http://linked.open...ain/vavai/riv/wos
  • 000311987000021
http://linked.open...n/vavai/riv/zamer
issn
  • 0165-1781
number of pages
http://bibframe.org/vocab/doi
  • 10.1016/j.psychres.2011.09.022
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software